Following a request from a group of shareholders representing more than 10 percent of the company shares (the "Minority Shareholders"), an extraordinary general meeting will be held on
The minority shareholders propose the election of four new members of the board, including Jan-Eric Österlund. All current members of the board today announce their decision to resign from their respective posts if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting.
The decision is based on the board having a different view than Jan-Eric Österlund on how regulatory requirements affect drug development, how the board's work is to be managed, and how to comply with the regulations on communication to shareholders and the market that applies for listed companies.
Isofol's current board of directors emphasizes the importance of not jeopardizing the assets of the company through hasty conclusions and initiatives. The board wishes to express its strong loyalty to the company and its overall goal - to enable continued development of the drug candidate arfolitixorin in a cost-effective and risk-minimized manner. The board acknowledges its intention to complete the stepwise strategy as communicated in
For more information, please contact
Mats Franzén, chairman of the board
E-mail: mats@efficere.se
Phone: +46 (0)704 47 29 09
The information was submitted for publication, through the agency of the contact person set out above, at
About
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/isofol-s-board-of-directors-announces-its-position-on-minority-shareholder-s-proposal-ahead-of-extra,c3892808
https://mb.cision.com/Main/15598/3892808/2491029.pdf
(c) 2023 Cision. All rights reserved., source